Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Cancerous human umbilical vein endothelial cell vaccine and application thereof in resisting cancers

A technology of endothelial cells and umbilical veins, applied in the direction of anti-tumor drugs, medical preparations containing active ingredients, cancer antigen components, etc., can solve problems such as limited effects, and achieve not easy to lose, long maintenance time, migration ability and invasion The effect of empowerment

Active Publication Date: 2018-08-10
ZHENGZHOU UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, relevant clinical experimental studies have found that although the vaccine can induce a certain degree of immune response in therapeutic immunity, the relevant effect is still relatively limited, so further optimization of the relevant treatment plan is required

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancerous human umbilical vein endothelial cell vaccine and application thereof in resisting cancers
  • Cancerous human umbilical vein endothelial cell vaccine and application thereof in resisting cancers
  • Cancerous human umbilical vein endothelial cell vaccine and application thereof in resisting cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0058] The tumorized HUVEC vaccine provided in this example is specifically prepared through the following steps:

[0059] (1) Collect the supernatant of CT26 cells,

[0060] In a 10cm culture dish, add 8ml of complete DMEM medium (10% BI serum + 90% DMEM) for routine culture of CT26 cells. When CT26 cells grow to occupy about 80% of the area of ​​the culture vessel (it takes about 2 days, the cells At 80%, the cell growth belongs to the exponential growth phase, the cell viability is the strongest, and the number is the largest, which is convenient to ensure the effect of the follow-up experiment). Wash once with PBS at room temperature, clean with a vacuum pump, and then add 5ml / dish of 1640 medium containing 10% volume fraction of G16 serum (a 10cm petri dish plus 5ml of G16 medium);

[0061] After culturing for 24 hours, collect the culture medium into a 15ml or 50ml centrifuge tube, centrifuge at 3000r / min for 5min, discard the precipitate, collect the supernatant into a...

experiment example

[0091] In order to test the difference in the anti-angiogenesis effect of the tumorized HUVEC vaccine prepared in the above examples and the existing HUVEC vaccine, the inventors further conducted animal experiments, which are briefly introduced as follows.

[0092] (1) Experimental grouping:

[0093] Feed female BALB / c mice (about 20-22g) aged 4-6 weeks in the barrier system, and randomly divide them into blank control group, endothelial cell group and tumorized endothelial cell group, with 7 mice in each group;

[0094] The feeding environment conditions are: temperature 20±2°C; relative humidity 50±10%; photoperiod 12h day / night; autoclaved SPF grade animal feed, litter and single distilled water; mice are free during the experiment Diet; Before the start of the experiment, the mice were pre-raised for one week to adapt to the environment;

[0095] (2) Experimental process:

[0096] After the experiment started, the corresponding vaccine was injected subcutaneously near t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of technical methods for preventing tumors, and in particular relates to a tumor microenvironment induced cancerous human umbilical vein endothelial cell vaccine andan application thereof in resisting angiogenesis of colon carcinoma. The vaccine is prepared by the following steps: collecting supernatant of CT26 cells, inducing HUVEC cells via the CT26 cell supernatant, collecting the HUVEC cells, immobilizing glutaraldehyde and the like. According to the invention, tumor vessel endothelial cells function as a target in tumor immnuotherapy, belonging to active immunotherapy. The cancerous HUVEC vaccine is prepared through inducing by an in-vitro simulated tumor microenvironment. Based upon preliminary experimental results, it is indicated that the prepared cancerous HUVEC vaccine can cause a more effective action in inhibiting tumor angiogenesis, and subsequently, an effect of resisting colon carcinoma growth can be developed; therefore, a relativelygood application effect can be achieved; and meanwhile, a new possibility is also provided for the application of a treatment method based on resisting tumor angiogenesis.

Description

technical field [0001] The invention belongs to the field of tumor prevention technology and method, and specifically relates to a patent application for a human umbilical vein endothelial cell vaccine induced by tumor microenvironment and its application in anti-tumor angiogenesis of colon cancer. Background technique [0002] Colon cancer is the second leading cause of cancer death worldwide, with more than 1.2 million new diagnoses and more than 600,000 annual deaths from the disease each year. In China, its morbidity and mortality rates rank third and fifth, respectively. Conventional treatment methods for this disease mainly include radical surgery and adjuvant treatment methods, such as commonly used chemotherapy and radiation therapy, which have been widely used in the treatment of colon cancer. But overall, the 5-year survival rate of colon cancer is still low, so there is an urgent need to develop new strategies to treat colon cancer. Among the new treatment strat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P35/00
CPCA61K39/0011A61K2039/5152A61P35/00
Inventor 路静王冬宇谢超杨艺晋果果刘行凡张秋爽邢莹董子明
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com